NAD+

NAD+ levels naturally decline with age — often by 50% or more in tissues by middle age — due to increased consumption (via CD38 enzyme activity and DNA repair demands) and reduced biosynthesis efficiency. This decline is linked in preclinical models to impaired mitochondrial function, metabolic slowdown, reduced sirtuin activity, and accelerated cellular aging processes. Key Findings from Recent Studies (2023–2026): • Human Clinical Trials on NAD+ Boosting: Oral precursors (NR and NMN) reliably increase whole-blood NAD+ levels by ~2-fold within 14 days in healthy adults. Direct NAD+ supplementation (including injectable/IV forms in clinical settings) has shown rapid elevation of NAD+ metabolites and improvements in biomarkers related to energy, inflammation, and oxidative stress. • Metabolic & Energy Support: Studies report enhanced insulin sensitivity, reduced inflammatory markers, and better mitochondrial efficiency. In conditions like chronic fatigue, Parkinson’s, and age-related metabolic decline, NAD+ augmentation has demonstrated preliminary benefits in quality-of-life measures, fatigue reduction, and physical performance. • Neuro & Cardiovascular Research: Early human data suggest potential improvements in cerebral perfusion, executive function, and vascular health. Animal models consistently show neuroprotection and cardiovascular resilience linked to restored NAD+ levels. • Longevity Pathways: NAD+ activates sirtuins (SIRT1, SIRT3), which regulate DNA repair, inflammation, and stress resistance — mechanisms heavily implicated in healthy aging.